Moderna’s New European Team Readies For COVID-19 Vaccine D-Day
Gearing Up For A Huge Commercial And Manufacturing Challenge
Executive Summary
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.
You may also be interested in...
AZ Will Sideline ‘Lucky Mistake’ To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Moderna Aces COVID-19 Vaccine Results With 94.5% Efficacy
Moderna’s stunning interim results add to the world’s relief brought by Pfizer’s first read-out, and also provide the US biotech with the commercial platform it needed
Beam Therapeutics’ Base-Edited CAR-T Placed On Hold
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.